TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28211169

Group type: EXPERIMENTAL
Intervention: DS-1040 (0.1 mg to 40 mg, administered as a 0.5-h intravenous infusion or as a 24-h continuous infusion)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: DS-1040
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 26742971

Group type: EXPERIMENTAL
Intervention: 100 U BoNTA
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 200 U BoNTA
Number of subjects: 80
Study: 23472879

Group type: EXPERIMENTAL
Intervention: NO₂⁻ infusion (0.31 to 7.8 μmol·min⁻¹)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: NO₂⁻ infusion
Number of subjects: 41
Study: 21676059

Group type: EXPERIMENTAL
Intervention: Initial ECG and early cardiac marker elevations
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Positive initial troponin
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Family history of coronary artery disease (CAD)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Abnormal ECG on arrival
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Elevated lipids
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Prior AMI
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Multivariable model including family history of CAD, abnormal initial ECG, and positive initial troponin
Number of subjects: 2000
Study: 19085579

Group type: EXPERIMENTAL
Intervention: Ciclesonide 640 micro g/day
Number of subjects: 1568

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate 640 micro g/day
Number of subjects: 1568
Study: 15367196

Group type: COMPARATOR
Intervention: Professional polishing with a rubber cup/point using dentifrice as abrasive paste for 10 min
Number of subjects: 90

Group type: COMPARATOR
Intervention: Professional brushing with an electric toothbrush (ETB) for 2 min
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Professional brushing with an electric toothbrush (ETB) for 10 min
Number of subjects: 90
Study: 10196018

Group type: EXPERIMENTAL
Intervention: Family history of chronic nephritis
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Susceptibility to the common cold
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Preference for salty foods
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Frequent consumption of raw eggs
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: High intake of carbohydrates (including rice)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Alcohol consumption
Number of subjects: 94

Group type: COMPARATOR
Intervention: Use of antioxidant vitamin supplements
Number of subjects: 94

Group type: COMPARATOR
Intervention: High intake of protein, fat, monounsaturated fatty acids, and all/n-3 polyunsaturated fatty acids
Number of subjects: 94

Group type: COMPARATOR
Intervention: Episodes of tonsillitis
Number of subjects: 94

Group type: COMPARATOR
Intervention: Exposure to organic solvents
Number of subjects: 94
Study: 7757360

Group type: EXPERIMENTAL
Intervention: Immunomodulating agents (specific agents not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemiluminescent analysis
Number of subjects: 0
Study: 2184637

Group type: EXPERIMENTAL
Intervention: Vincristine (0.02 to 0.04 mg/kg)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Vinblastine (0.1 to 0.2 mg/kg)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Vincristine and Vinblastine (combined)
Number of subjects: 38
Study: 760738

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg intravenous injection
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Bromocriptine pretreatment
Number of subjects: 4

Group type: COMPARATOR
Intervention: Cimetidine 800 mg oral dose
Number of subjects: 4

Group type: COMPARATOR
Intervention: Cimetidine treatment (various doses)
Number of subjects: 4
Study: 30039982

Group type: EXPERIMENTAL
Intervention: KH-204
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control
Number of subjects: 78
Study: 30740933

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 54
Study: 27873094

Group type: EXPERIMENTAL
Intervention: EBR (50 mg) + GZR (50 mg) for 12 weeks
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: EBR (50 mg) + GZR (100 mg) for 12 weeks
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Immediate treatment with EBR (50 mg) + GZR (100 mg) for 12 weeks (noncirrhotic patients)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Immediate treatment with EBR (50 mg) + GZR (100 mg) for 12 weeks (cirrhotic patients)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Deferred treatment with EBR (50 mg) + GZR (100 mg) for 12 weeks (noncirrhotic patients)
Number of subjects: 336
Study: 25602456

Group type: EXPERIMENTAL
Intervention: nCPAP (N = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard oxygen mask management (Control group, N = 20)
Number of subjects: 40
Study: 25191890

Group type: EXPERIMENTAL
Intervention: Zirconia implants (test group)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Titanium implants (control group)
Number of subjects: 19
Study: 22710004

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study: 19049326

Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg once a week
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study: 17333359

Group type: EXPERIMENTAL
Intervention: Early Risers 'Skills for Success' intervention
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 151
Study: 15247111

Group type: EXPERIMENTAL
Intervention: Epidural block
Number of subjects: 60

Group type: COMPARATOR
Intervention: Combined femoral (3‐in‐1) and sciatic blocks
Number of subjects: 60
Study: 11441529

Group type: EXPERIMENTAL
Intervention: Vitamin C (C-test)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (P-test)
Number of subjects: 18
Study: 9710370

Group type: EXPERIMENTAL
Intervention: Residential RCMS magnetic field exposures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RCMS exposures during work
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined RCMS exposures at work and home
Number of subjects: 0

Group type: COMPARATOR
Intervention: Magnetic field intensity, intermittence, or cumulative exposure
Number of subjects: 0
Study: 7988012

Group type: EXPERIMENTAL
Intervention: LDL cholesterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cholesterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Apolipoprotein B (apoB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipoprotein(a) [Lp(a)]
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-density lipoprotein (HDL) cholesterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ApoA-I
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thyroid hormones
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Von Willebrand factor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-load plasma glucose and insulin concentrations
Number of subjects: 0
Study: 2743469

Group type: EXPERIMENTAL
Intervention: Somophyllin-CRT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TheoDur
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous aminophylline infusion
Number of subjects: 0
Study: 31058633

Group type: EXPERIMENTAL
Intervention: Salivary bacterial count among participants
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Poor oral hygiene
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Periodontitis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Male sex and increasing age
Number of subjects: 60
Study: 28288075

Group type: EXPERIMENTAL
Intervention: EHR-embedded best practice alert (BPA) for HCV testing
Number of subjects: 25620

Group type: COMPARATOR
Intervention: Control group (no BPA)
Number of subjects: 25620
Study: 25885106

Group type: EXPERIMENTAL
Intervention: liraglutide 1.2 mg QD sc
Number of subjects: 32

Group type: COMPARATOR
Intervention: metformin 1000 mg BID po
Number of subjects: 32
Study: 23612494

Group type: EXPERIMENTAL
Intervention: Intranasal Botulinum Toxin‐A (75IU Dysport®)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cetirizine (10mg/day)
Number of subjects: 50
Study: 21197615

Group type: EXPERIMENTAL
Intervention: Oxazepam (20 mg p.o.)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 18580064

Group type: EXPERIMENTAL
Intervention: Beating heart technique (n = 22)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Cardioplegic cardiac arrest technique (n = 23)
Number of subjects: 45
Study: 17531691

Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 5011

Group type: COMPARATOR
Intervention: Retrobulbar anesthesia
Number of subjects: 5011

Group type: EXPERIMENTAL
Intervention: Topical anesthesia (extended study period)
Number of subjects: 5011

Group type: COMPARATOR
Intervention: Retrobulbar anesthesia (extended study period)
Number of subjects: 5011
Study: 15364759

Group type: EXPERIMENTAL
Intervention: nCPAP therapy (during application)
Number of subjects: 32

Group type: COMPARATOR
Intervention: nCPAP therapy (before application)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Wakefulness
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 32
Study: 11589843

Group type: EXPERIMENTAL
Intervention: Sublingual apomorphine 5 mg
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 9647968

Group type: EXPERIMENTAL
Intervention: Esterified estrogens plus methyltestosterone for four and eight weeks of daily drug administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Esterified estrogens alone for four and eight weeks of daily drug administration
Number of subjects: 0
Study: 7991990

Group type: EXPERIMENTAL
Intervention: c-erbB-2 protein expression in early stomach cancers
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: c-erbB-2 protein expression in advanced stomach cancers
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: c-erbB-2 protein expression in recurrent or inoperable metastatic stomach cancers
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: c-erbB-2 protein levels in serum of patients with primary stomach cancers
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: c-erbB-2 protein levels in serum of patients with recurrent or inoperable metastatic stomach cancers
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: c-erbB-2 protein levels during chemotherapy in recurrent or inoperable metastatic disease
Number of subjects: 309
Study: 2647667

Group type: EXPERIMENTAL
Intervention: Relaxation training (stepwise relaxation/hypnosis/autogenic training/cognitive behavior therapy)
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Biofeedback (thermal/photoplethysmograph/EMG)
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Micro-electrical therapy (TENS/Neurotransmitter Modulation)
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Multimodal treatment (combination of any of the above two treatments)
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Short term intervention (15 or less treatments)
Number of subjects: 1015

Group type: EXPERIMENTAL
Intervention: Long term intervention (greater than 15 treatments)
Number of subjects: 1015
Study: 31955968

Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine combined with 0.3 μg/mL sufentanil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil combined with 0.1% ropivacaine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Labor analgesia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 60
Study: 31745043

Group type: EXPERIMENTAL
Intervention: Mouthwash containing essential oils and curcumin (MEC) as an adjunct to scaling and root planing (SRP)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouthwash as an adjunct to scaling and root planing (SRP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 45
Study: 28289044

Group type: EXPERIMENTAL
Intervention: Friendship-based network-targeting algorithm with established care interventions
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: Scalable methods of network targeting
Number of subjects: 30000
Study: 24668575

Group type: EXPERIMENTAL
Intervention: Intrathecal 0.5% isobaric levobupivacaine with 25 mcg fentanyl
Number of subjects: 100
Study: 23869899

Group type: EXPERIMENTAL
Intervention: Partners in Dementia Care (PDC) program
Number of subjects: 486
Study: 20965956

Group type: EXPERIMENTAL
Intervention: Retransfusion of pericardial blood
Number of subjects: 13

Group type: COMPARATOR
Intervention: Discarding pericardial blood
Number of subjects: 13
Study: 18325150

Group type: EXPERIMENTAL
Intervention: Referral to Community Mental Health Teams (CMHTs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Direct doctor-to-doctor communication strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Development of intermediate or 'Tier 2' services
Number of subjects: 0
Study: 17129547

Group type: EXPERIMENTAL
Intervention: Prednisone 40 mg daily for 4 weeks, followed by 2 weeks without treatment, and lamivudine 150 mg daily for 4 weeks; followed by lamivudine plus interferon alfa 2b (10 MIU every other day) for 24 weeks and continuous lamivudine 150 mg daily to complete 58 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Lamivudine 150 mg daily for 4 weeks plus interferon alfa 2b (10 MIU every other day) for 24 weeks, without prednisone
Number of subjects: 44
Study: 15361771

Group type: EXPERIMENTAL
Intervention: Daily fish meal
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Weight-reduction regimen
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Combined fish meal and weight loss
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study: 11328261

Group type: EXPERIMENTAL
Intervention: Biologically-derived porcine secretin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Synthetic porcine secretin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Synthetic human secretin
Number of subjects: 6
Study: 9309708

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (36‐38 mg/kg/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 8358976

Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 3739805

Group type: EXPERIMENTAL
Intervention: Medium drinkers consuming an experimental dose similar to their usual dose
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Light drinkers
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Heavy drinkers consuming a dose lower than their usual dose
Number of subjects: 60
Study: 28971273

Group type: EXPERIMENTAL
Intervention: GTO training, tools, and technical assistance
Number of subjects: 32

Group type: COMPARATOR
Intervention: Making Proud Choices (MPC) without GTO
Number of subjects: 32
Study: 26932401

Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 280

Group type: COMPARATOR
Intervention: MOAA/S monitoring
Number of subjects: 280
Study: 24559846

Group type: EXPERIMENTAL
Intervention: HFD + stearate (9g/d of encapsulated stearate)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: HFD + linoleate (9g/d of encapsulated linoleate)
Number of subjects: 100

Group type: COMPARATOR
Intervention: HFD + placebo
Number of subjects: 100
Study: 22658300

Group type: EXPERIMENTAL
Intervention: Left atrial volume index (LAVI) > 32 ml/m(2)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Left ventricular mass (LVM) indexed to height(2.7)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Natural logarithm BNP
Number of subjects: 130

Group type: COMPARATOR
Intervention: Blood pressure levels, body mass index, age
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Parameters of LV diastolic function
Number of subjects: 130
Study: 20886787

Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion
Number of subjects: 80

Group type: COMPARATOR
Intervention: Medication (Sodium Hyaluronate eye drops, 1 drop three times per day)
Number of subjects: 80
Study: 18178395

Group type: EXPERIMENTAL
Intervention: Statin pretreatment
Number of subjects: 253
Study: 15807861

Group type: EXPERIMENTAL
Intervention: Alum-precipitated autoclaved Leishmania major (Alum/ALM) +/‐ bacille Calmette‐Guerin (BCG)
Number of subjects: 44
Study: 14656785

Group type: EXPERIMENTAL
Intervention: Ultrasound imaging (UG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional method using loss of resistance technique (CG)
Number of subjects: 60
Study: 10721929

Group type: EXPERIMENTAL
Intervention: 60 mg iron as ferrous sulfate daily from Monday to Friday
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: 60 mg iron as ferrous sulfate 2 d/wk and 3 d placebo (intermittent)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo from Monday to Friday
Number of subjects: 312
Study: 9188929

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (200 micrograms once daily for 4 weeks)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Loratadine (10 mg once daily for 4 weeks)
Number of subjects: 114
Study: 1348000

Group type: EXPERIMENTAL
Intervention: salmeterol (50 micrograms, 8.3 x 10(‐8) M)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: salbutamol (200 micrograms, 3.5 x 10(‐7) M)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: salmeterol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: salbutamol
Number of subjects: 10
Study: 3549875

Group type: EXPERIMENTAL
Intervention: 0.6 mg atropine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.2 mg glycopyrrolate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30099126

Group type: EXPERIMENTAL
Intervention: Noncontrast computed tomographic urography
Number of subjects: 475

Group type: COMPARATOR
Intervention: Contrast-enhanced computed tomographic urography
Number of subjects: 475
Study: 26331692

Group type: EXPERIMENTAL
Intervention: GW406381 (COX-2 inhibitor)
Number of subjects: 400
Study: 25352893

Group type: EXPERIMENTAL
Intervention: Funnel technique
Number of subjects: 14

Group type: COMPARATOR
Intervention: Magerl technique
Number of subjects: 14
Study: 23387245

Group type: EXPERIMENTAL
Intervention: Yoga Nidra practice (35-40 minutes/day, five days a week for six months)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 150
Study: 20457702

Group type: EXPERIMENTAL
Intervention: Hormonal treatment
Number of subjects: 77

Group type: COMPARATOR
Intervention: Vigabatrin
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Hormonal treatment (no identified aetiology)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Vigabatrin (no identified aetiology)
Number of subjects: 77
Study: 18971490

Group type: EXPERIMENTAL
Intervention: Early insulin therapy (continuous infusion of insulin at a dose of 0.05 U/kg/hour with 20% dextrose support)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Early insulin therapy
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control group (standard neonatal care)
Number of subjects: 195
Study: 15897845

Group type: EXPERIMENTAL
Intervention: 50 mg oral rofecoxib
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 400 mg ibuprofen
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 12634885

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic therapy (e.g. amiodarone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy and angiotensin converting enzyme inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 0
Study: 9684946

Group type: EXPERIMENTAL
Intervention: 300 mg/kg Hypericum extract (WS 5572, containing 5% hyperforin) in rats
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 300 mg hypericum extracts (14.8 mg hyperforin) in human volunteers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated dose of 3 x 300 mg/day of the extract in human volunteers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing doses of 900 or 1200 mg of extract in human volunteers
Number of subjects: 0
Study: 10155065

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 742
Study: 2965126

Group type: EXPERIMENTAL
Intervention: 400 mg teicoplanin given intravenously on induction of anaesthesia
Number of subjects: 146

Group type: COMPARATOR
Intervention: Three perioperative injections of cefuroxime
Number of subjects: 146
Study: 29212987

Group type: EXPERIMENTAL
Intervention: Higher quintiles of estimated CHD risk per prediction model
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: All prediction models
Number of subjects: 996
Study: 26970533

Group type: EXPERIMENTAL
Intervention: Maintenance Rituximab (MR) - single dose rituximab every 3 months until treatment failure
Number of subjects: 131

Group type: COMPARATOR
Intervention: Retreatment Rituximab (RR) - rituximab weekly for 4 weeks at the time of each progression until treatment failure
Number of subjects: 131

Group type: COMPARATOR
Intervention: Retreatment Rituximab (RR)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Maintenance Rituximab (MR)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Both MR and RR
Number of subjects: 131
Study: 23839225

Group type: EXPERIMENTAL
Intervention: Special Needs Diversionary Program (SNDP)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Other court‐ordered programs
Number of subjects: 328
Study: 23782594

Group type: EXPERIMENTAL
Intervention: 50 mg canagliflozin
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: 100 mg canagliflozin
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: 200 mg canagliflozin
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: 300 mg canagliflozin
Number of subjects: 383

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383
Study: 21656474

Group type: EXPERIMENTAL
Intervention: AVF ligature (group A)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Transvenous endovenorrhaphy (group B)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Transvenous endovenorrhaphy (for recurrences)
Number of subjects: 162